ARCA biopharma(ABIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABIO ARCA biopharma

Closed Christmas Day 08-30 16:00:00 EDT

28.80

+0.00

0.00%

High28.80	Low28.80	Vol0.00
Open28.80	D1 Closing28.80	Amplitude0.00%
Mkt Cap849.32M	Tradable Cap137.90M	Total Shares29.49M
T/O688.27K	T/O Rate0.00%	Tradable Shares4.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABIO","market":"US","secType":"STK","nameCN":"ARCA biopharma","latestPrice":28.8,"timestamp":1725048000000,"preClose":28.8,"halted":8,"volume":0,"delay":0,"floatShares":4788181,"shares":29490443,"eps":-0.497828,"marketStatus":"Closed Christmas Day","change":0,"latestTime":"08-30 16:00:00 EDT","open":28.8,"high":28.8,"low":28.8,"amount":688271.496256,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.497828,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735203600000},"marketStatusCode":7,"symbolChange":{"newSymbol":"ORKA","executeDate":"2024-09-03"},"adr":0,"adrRate":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":28.8,"volumeRatio":0},"requestUrl":"/m/hq/s/ABIO/wiki","defaultTab":"wiki","newsList":[{"id":"2464874308","title":"BRIEF-Oruka Therapeutics Announces Closing of Merger with ARCA biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2464874308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464874308?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:14","pubTimestamp":1725362058,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - Oruka Therapeutics Inc   :   * ORUKA THERAPEUTICS ANNOUNCES CLOSING OF MERGER WITH ARCA BIOPHARMA AND PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT OF $275 MILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABIO","LENZ","BK4139"],"gpt_icon":0},{"id":"2464879024","title":"Press Release: Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2464879024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464879024?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:00","pubTimestamp":1725361200,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million. Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions. Company on track to advance co-lead programs, ORKA-001 and ORKA-002, into the clinic and show initial pharmacokinetic data for ORKA-001 next year. Samarth Kulkarni, PhD, appointed Chairman of Oruka's Board of Directors. Shares to trade on Nasdaq under the ticker symbol \"ORKA\" commencing today, September 3, 2024. \"Oruka's product candidates have incredible potential to change the landscape of treatment for multiple diseases,\" commented Samarth Kulkarni, PhD. \"I am very impressed with the work the team has completed to date and believe they are well positioned to deliver on the immense promise","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1861558580.USD","BK4588","IE00BHPRN162.USD","BK4227","IE00B7SZLL34.SGD","BK4585","BK4554","LU1861559042.SGD","BK4551","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","BK4581","BK4528","BK4503","BK4106","LENZ","ABIO"],"gpt_icon":0},{"id":"2464837142","title":"Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested","url":"https://stock-news.laohu8.com/highlight/detail?id=2464837142","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464837142?lang=en_us&edition=fundamental","pubTime":"2024-09-02 21:21","pubTimestamp":1725283284,"startTime":"0","endTime":"0","summary":"These are the upcoming stock splits for the week of September 2 to September 6, based onTipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares . In this case, too, the market cap is maintained as the share price increases following the reverse stock split.Companies often undertake stock splits to improve the liquidity of the common shares and make them more affordable for retail investors. Let’s look quickly at the upcoming stock splits for the week.White River Bancshares Co.  – White River Bancshares operates through its wholly-owned community banking subsidiary, Signature Bank of Arkansas. The bank offers personal banking, business, and wealth manag","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jf7o_NnWA1MZuMBX7sSJrg--~B/aD0yNTI7dz02OTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/af39c9895f7880054efff14f6a7c2eb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jf7o_NnWA1MZuMBX7sSJrg--~B/aD0yNTI7dz02OTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/af39c9895f7880054efff14f6a7c2eb2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-september-132124362.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-september-132124362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4162","BK4122","LNC","EGRAF","DPRO","BK4220","BK4585","ABIO","BK4139","WRIV","BK4156","MTNB","OIBRQ","BK4115","BK4187","OIBZQ","LITB","BK4588"],"gpt_icon":0},{"id":"2463321187","title":"ARCA Biopharma Closes Merger With Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2463321187","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463321187?lang=en_us&edition=fundamental","pubTime":"2024-08-30 06:03","pubTimestamp":1724969037,"startTime":"0","endTime":"0","summary":"ARCA Biopharma  said late Thursday that it completed its merger with Oruka Therapeutics following a stockholder approval at a special meeting on Aug. 22.In addition, the combined company will implement a reverse stock split at a ratio of 1-for-12 shares, the company said.The combined company will operate under Oruka Therapeutics, with shares to begin trading on a post-reverse split on Nasdaq under the ORKA ticker symbol from Sept. 3.Price: 2.5500, Change: +0.05, Percent Change: +2.00","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABIO","BK4139","LENZ"],"gpt_icon":0},{"id":"2463921386","title":"ARCA Biopharma Inc - Combined Company Will Implement a Reverse Split of Its Common Stock at a Ratio of 1-for-12 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2463921386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463921386?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:50","pubTimestamp":1724964615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nTUA37FKFY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABIO","BK4139"],"gpt_icon":0},{"id":"2463866213","title":"ARCA Biopharma Announces Completion of Merger With Oruka Therapeutics and Implementation of Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2463866213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463866213?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:50","pubTimestamp":1724964615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nTUA37FKFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABIO"],"gpt_icon":0},{"id":"2463321384","title":"ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2463321384","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463321384?lang=en_us&edition=fundamental","pubTime":"2024-08-30 04:50","pubTimestamp":1724964600,"startTime":"0","endTime":"0","summary":"The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024WESTMINSTER, Colo., Aug.  29, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/29/2938141/0/en/ARCA-biopharma-Announces-Completion-of-Merger-with-Oruka-Therapeutics-and-Implementation-of-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABIO","BK4139","LENZ"],"gpt_icon":0},{"id":"2462533976","title":"ARCA Biopharma Provides Update Regarding Special Dividend Amount in Connection With the Proposed Merger With Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2462533976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462533976?lang=en_us&edition=fundamental","pubTime":"2024-08-27 07:30","pubTimestamp":1724715000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240826:nTUA5F8BTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABIO","BK4139"],"gpt_icon":0},{"id":"2462769639","title":"ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2462769639","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462769639?lang=en_us&edition=fundamental","pubTime":"2024-08-27 07:30","pubTimestamp":1724715000,"startTime":"0","endTime":"0","summary":"WESTMINSTER, Colo., Aug.  26, 2024  (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/26/2935864/0/en/ARCA-biopharma-Provides-Update-Regarding-Special-Dividend-Amount-in-Connection-with-the-Proposed-Merger-with-Oruka-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","LENZ","PSQ","ABIO","QLD","NQmain","MNQmain",".IXIC","BK4139","SQQQ","TQQQ"],"gpt_icon":1},{"id":"2462875992","title":"ARCA biopharma declares $1.59 special dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2462875992","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462875992?lang=en_us&edition=fundamental","pubTime":"2024-08-26 20:25","pubTimestamp":1724675114,"startTime":"0","endTime":"0","summary":"ARCA biopharma (NASDAQ:ABIO) declares $1.59/share special dividend.\nPayable Aug. 28; for shareholders of record Aug. 26; ex-div Aug. 26.\nSee ABIO Dividend Scorecard, Yield Chart, & Dividend Growth.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4143656-arca-biopharma-declares-159-special-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QID","US5Y.BOND","SQQQ","US3Y.BOND","US30Y.BOND","US912797HE00.BOND","NQmain","US7Y.BOND","QLD","MNQmain","PSQ","US12M.BOND",".IXIC","US6M.BOND","US912797GW17.BOND","US10Y.BOND","ABIO","BK4139","US2Y.BOND","TQQQ","US912797GL51.BOND"],"gpt_icon":1},{"id":"2461524483","title":"BRIEF-Arca Biopharma Announces 1-For-12 Reverse Stock Split In Connection With The Proposed Merger With Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2461524483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461524483?lang=en_us&edition=fundamental","pubTime":"2024-08-24 06:15","pubTimestamp":1724451334,"startTime":"0","endTime":"0","summary":"Aug 23 (Reuters) - ARCA Biopharma Inc   :   * ARCA BIOPHARMA ANNOUNCES 1-FOR-12 REVERSE STOCK SPLIT IN CONNECTION WITH THE PROPOSED MERGER WITH ORUKA THERAPEUTICSSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABIO","BK4139","LENZ"],"gpt_icon":0},{"id":"2461037529","title":"ARCA biopharma approves 1-for-12 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2461037529","media":"seekingalpha","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461037529?lang=en_us&edition=fundamental","pubTime":"2024-08-24 05:37","pubTimestamp":1724449069,"startTime":"0","endTime":"0","summary":"Pharmaceutical company ARCA biopharma  said on Friday its board has approved a reverse stock split of its shares at a ratio of 1-for-12. ARCA’s  stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on September 3, 2024.  The company’s stock will trade under the new name Oruka Therapeutics, and under the new symbol “ORKA” after the closing of its merger with Oruka. The reverse stock split is expected to reduce ARCA ’s common shares from about 14.5M shares to about 1.2M shares. ARCA’s shares were down 3.85% during after-hours trading.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301873080/image_1301873080.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301873080/image_1301873080.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4143514-arca-biopharma-approves-1-for-12-reverse-stock-split","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QID","TQQQ","QLD","PSQ","MNQmain","NQmain",".IXIC","BK4139","SQQQ","ABIO"],"gpt_icon":1},{"id":"2461525355","title":"ARCA biopharma to Implement 1-For-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2461525355","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461525355?lang=en_us&edition=fundamental","pubTime":"2024-08-24 04:49","pubTimestamp":1724446185,"startTime":"0","endTime":"0","summary":"ARCA biopharma  said Friday its board approved a 1-for-12 reverse stock split of its shares.The shares will start trading on a split-adjusted basis on Sept. 3 under the new name, Oruka Therapeutics, and under the new symbol \"ORKA\" following the expected closing of its merger with Oruka, the firm said.Price: 4.3400, Change: +0.18, Percent Change: +4.33","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABIO","BK4139"],"gpt_icon":0},{"id":"2461525311","title":"ARCA biopharma to Implement 1-For-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2461525311","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461525311?lang=en_us&edition=fundamental","pubTime":"2024-08-24 04:49","pubTimestamp":1724446185,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["ABIO","BK4139","LENZ"],"gpt_icon":0},{"id":"2461528207","title":"ARCA Biopharma Announces 1-for-12 Reverse Stock Split in Connection With the Proposed Merger With Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2461528207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461528207?lang=en_us&edition=fundamental","pubTime":"2024-08-24 04:30","pubTimestamp":1724445000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240823:nTUA3JFKBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABIO"],"gpt_icon":0},{"id":"2461523814","title":"ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2461523814","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461523814?lang=en_us&edition=fundamental","pubTime":"2024-08-24 04:30","pubTimestamp":1724445000,"startTime":"0","endTime":"0","summary":"WESTMINSTER, Colo., Aug.  23, 2024  (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/23/2935088/0/en/ARCA-biopharma-Announces-1-for-12-Reverse-Stock-Split-in-Connection-with-the-Proposed-Merger-with-Oruka-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ABIO","BK4139"],"gpt_icon":0},{"id":"2461835840","title":"We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2461835840","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461835840?lang=en_us&edition=fundamental","pubTime":"2024-08-21 02:51","pubTimestamp":1724179898,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should ARCA biopharma  shareholders be worried about its cash burn?In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since it has a market capitalisation of US$43m, ARCA biopharma's US$6.9m in cash burn equates to about 16% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-arca-185138321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","PSQ","BK4585","MNQmain","TQQQ","LU2095319765.USD","LU2210149790.SGD","BK4112","BK4139","LU2210150020.SGD","NDAQ","ABIO","QID","SQQQ","NQmain","IE00BKPKM429.USD",".IXIC","QLD"],"gpt_icon":1},{"id":"2460687050","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2460687050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460687050?lang=en_us&edition=fundamental","pubTime":"2024-08-20 02:02","pubTimestamp":1724090572,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4142","ABIO","LU1718418525.SGD","BK4139","BK4539","ALZN","BK4588","MAR.AU","MAR","SOND","BK4585"],"gpt_icon":0},{"id":"2460050663","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2460050663","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460050663?lang=en_us&edition=fundamental","pubTime":"2024-08-20 02:02","pubTimestamp":1724090572,"startTime":"0","endTime":"0","summary":"Alzamend Neuro (ALZN) shares skyrocketed 356% after the company said Monday that Massachusetts General Hospital will be its contract research organization to conduct a phase 2 clinical study of AL001 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","ALZN","BK4588","ABIO","MAR","BK4539","LU1718418525.SGD","BK4139","MAR.AU","BK4142","SOND"],"gpt_icon":1},{"id":"2460701502","title":"Estée Lauder, Palo Alto Networks And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2460701502","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460701502?lang=en_us&edition=fundamental","pubTime":"2024-08-19 15:47","pubTimestamp":1724053659,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40434829/est-e-lauder-palo-alto-networks-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU2125909759.SGD","BK4581","LU1989764748.USD","LU1169590202.USD","BK4183","EL","LU1923622291.USD","BK4097","LU2286300806.USD","IE00BMPRXR70.SGD","BK4532","IE00B19Z4B17.USD","BK4558","LU2404859667.USD","LU0234570918.USD","LU1861220033.SGD","ABIO","LU2552382058.USD","FN","LU2552382132.HKD","LU2045819591.USD","BK4504","BK4585","LU2357305700.SGD","LU1720051108.HKD","IE0031619046.USD","IE00B19Z8W00.USD","LU2404859741.USD","LU2023250504.SGD","LU2552382215.SGD","LU1861215975.USD","LU2023250843.SGD","BK4550","LU2125909916.SGD","LU0690374961.EUR","LU2265009873.SGD","LU1720051017.SGD","ZIM","LU0348723411.USD","IE00BMPRXN33.USD","BK4560","LU1974910355.USD","LU1989764664.SGD","BK4021","PANW","LU2125910500.SGD","BK4548","LU0690374615.EUR","IE00B19Z8X17.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.arcabiopharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":-0.3333},{"period":"1year","weight":0.4035},{"period":"ytd","weight":0.4118}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.061348},{"month":2,"riseRate":0.375,"avgChangeRate":-0.063833},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.030249},{"month":4,"riseRate":0.5625,"avgChangeRate":0.101192},{"month":5,"riseRate":0.5,"avgChangeRate":0.09678},{"month":6,"riseRate":0.25,"avgChangeRate":0.477078},{"month":7,"riseRate":0.5,"avgChangeRate":0.014024},{"month":8,"riseRate":0.0625,"avgChangeRate":-0.146138},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.075747},{"month":10,"riseRate":0.4,"avgChangeRate":-0.066754},{"month":11,"riseRate":0.666667,"avgChangeRate":0.018484},{"month":12,"riseRate":0.533333,"avgChangeRate":0.003511}],"exchange":"NASDAQ","name":"ARCA biopharma","nameEN":"ARCA biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARCA biopharma(ABIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARCA biopharma(ABIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARCA biopharma,ABIO,ARCA biopharma股票,ARCA biopharma股票老虎,ARCA biopharma股票老虎国际,ARCA biopharma行情,ARCA biopharma股票行情,ARCA biopharma股价,ARCA biopharma股市,ARCA biopharma股票价格,ARCA biopharma股票交易,ARCA biopharma股票购买,ARCA biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARCA biopharma(ABIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARCA biopharma(ABIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction